342
Views
24
CrossRef citations to date
0
Altmetric
Research Article

Haemostatic therapy in coronary artery bypass graft patients with decreased platelet function: Comparison of fibrinogen concentrate with allogeneic blood products

, , , , , & show all
Pages 121-128 | Received 15 May 2011, Accepted 10 Nov 2011, Published online: 10 Jan 2012
 

Abstract

Background. Patients undergoing coronary artery bypass grafting (CABG) are at risk of postoperative bleeding because of decreased platelet function and cardiopulmonary bypass (CPB)-induced haemostatic impairment. Fibrinogen concentration decreases by 34–42% of the preoperative level by the end of CPB. An inverse relationship between perioperative plasma fibrinogen levels and postoperative bleeding has been reported in CABG patients. Administration of fibrinogen concentrate after weaning from CPB in patients with diffuse microvascular bleeding may help promote haemostasis. We compared patient outcomes following fibrinogen concentrate administration or transfusion of allogeneics in CABG patients with decreased platelet function. Methods. Thirty-eight patients with decreased preoperative platelet function in Multiplate aggregometry were included. Patients with bleeding after CPB received either fibrinogen concentrate (guided by the measurement of fibrin clot quality using the FIBTEM thromboelastometric test) or allogeneics. Results. Twenty-nine of 38 patients received haemostatic therapy (bleeding + fibrinogen group, n = 10; bleeding + allogeneics group, n = 19). Total transfusion (median (interquartile range)) was significantly lower in the bleeding + fibrinogen group (0 (0, 3.8) units), compared with the bleeding + allogeneics group (6 (5, 8) units, p = 0.0073). Bolus administration of fibrinogen concentrate increased FIBTEM maximum clot firmness from 10.5 (9.3, 11) mm after CPB to 20.5 (20, 21.8) mm at the end of surgery. Postoperative outcomes were similar in both groups. No treatment-related complications were observed after fibrinogen concentrate. Conclusions. In CABG patients with bleeding after CPB, FIBTEM-guided administration of fibrinogen concentrate resulted in overall decreased transfusion, compared with haemostatic therapy with allogeneics. Fibrinogen concentrate administration increased the fibrin clot quality and helped achieve haemostasis.

Acknowledgements

Data collection was supported by an unrestricted research grant from CSL Behring. Editorial assistance with the development of this manuscript was provided by Jo Millership of Fishawack Communications Ltd. Financial support for this assistance was provided by CSL Behring GmbH

Declaration of interest: Drs Solomon, Schöchl and Tanaka have received honoraria as speakers and research support from CSL Behring (manufacturer of fibrinogen concentrate) and Tem International GmbH (manufacturer of the TEM device). Dr Hanke has received honoraria as speaker and research support from CSL Behring. Dr Calatzis is co-inventor of Multiple Electrode Aggregometry. Prof. Dr Niels Rahe-Meyer has participated in advisory boards and has received speaker honoraria and research support from CSL Behring and Tem International. Dr Hagl has no conflicts of interest to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.